Analysts fell to the sidelines weighing in on Bristol-Myers Squibb (BMY – Research Report) and Agios Pharma (AGIO – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Bristol-Myers Squibb (BMY)
In a report issued on October 31, David Risinger from Leerink Partners maintained a Hold rating on Bristol-Myers Squibb. The company’s shares closed last Monday at $55.45, close to its 52-week high of $56.20.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Bristol-Myers Squibb with a $53.79 average price target, a -1.0% downside from current levels. In a report issued on October 17, Bernstein also initiated coverage with a Hold rating on the stock with a $56.00 price target.
See today’s best-performing stocks on TipRanks >>
Agios Pharma (AGIO)
Leerink Partners analyst Andrew Berens reiterated a Hold rating on Agios Pharma on October 31 and set a price target of $56.00. The company’s shares closed last Monday at $44.83.
According to TipRanks.com, Berens ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Agios Pharma has an analyst consensus of Strong Buy, with a price target consensus of $54.20.
Read More on BMY:
- Bristol-Myers Squibb’s (NYSE:BMY) Schizophrenia Drug Sees Positive Results
- Silexion Therapeutics initiated with a Buy at Maxim
- Bristol Myers price target raised to $60 from $55 at BofA
- Bristol Myers Squibb Posts Robust Q3 2024 Growth
- Bristol Myers presents new long-term data from EMERGENT study of COBENFY
